Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-09-27
2005-09-27
Clardy, S. Mark (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S172000, C514S176000, C514S182000, C514S828000, C514S958000
Reexamination Certificate
active
06949532
ABSTRACT:
The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
REFERENCES:
patent: 4472393 (1984-09-01), Shapiro
patent: 6127353 (2000-10-01), Yuen et al.
patent: 2062854 (1992-09-01), None
patent: 0 518 600 (1992-12-01), None
patent: 0 518 601 (1992-12-01), None
patent: WO 92/04365 (1992-03-01), None
patent: WO 92/06706 (1992-04-01), None
H. A. Orgel et al., “Clinical, Rhinomanometric, and Cytologic Evaluation of Seasonal Allergic Rhinitis Treated with Beclomethasone Dipropionate as Aqueous Nasal Spray or Pressurized Aerosol,”Journal of Allergy and Clinical Immunology, vol. 77, pp. 858-864, 1986.
PR Newswire, Nov. 30, 1988, 4 pages.
J. M. Swinehart et al., “Mometasone Furoate Lotion Once Daily. Versus Triamcinolone Acetonide Lotion Twice Daily in Psoriasis,”International Journal of Dermatology, vol. 28, pp. 680-681, 1989.
H. J. Lee et al., “Anti-Inflammatory Steroids: Research Trends and New Compounds,”Drugs of Today, vol. 25, pp. 577-588, 1989.
P. Viglioglia et al., “Once-Daily 0.1% Mometasone Furoate Cream Versus Twice-Daily 0.1% Betamethasone Valerate Cream in the Treatment of a Variety of Dermatoses,”The Journal of International Medical Research, vol. 18, pp. 460-467, 1990.
Business Wire, Nov. 14, 1990, 5 pages.
J. W. Kelly et al., “Safety and Efficacy of Mometasone Furoate Cream in the Treatment of Steroid Responsive Dermatoses,”Australian Journal of Dermatology, vol. 32, pp. 85-91, 1991.
S. Lidén, “Optimal Efficacy of Topical Corticoids in Psoriasis,”Seminars in Dermatology, vol. 11, pp. 275-277, 1992.
Predicasts Marketletter, Mar. 30, 1992, 3 pages.
I. M. Richards et al., “Novel Steroid-Based Inhibitors of Lung Inflammation,”Clinical and Experimental Allergy, vol. 22, pp. 432-439, 1992.
C. J. Wang et al., “A Senstive Enzyme Immunoassay (EIA) for Quantitation of Mometasone Furoate (SCH 32088) Directly in Biological Fluids,” Abstract 2119,FASEB J., vol. 6, No. 4, p. A1302, 1992.
C-J. Wang et al., “A Competitive Enzyme Immunoassay for the Direct Determination of Mometasone Furoate (SCH 32088) in Human Plasma,”Journal of Pharmaceutical and Biomedical Analysis, vol. 10, pp. 473-479, 1992.
H. Degreef et al., “The New Corticosteroids: Are They Effective and Safe?”Dermatologic Clinics, vol. 11, pp. 155-160, 1993.
D. Debrovner, “Why Asthmatics Need You,”American Druggist, pp. 24-27, Aug. 1994.
M. Drouin et al., “Once Daily Mometasone Furoate Aqueous Nasal Spray is as Effective as Twice Daily Beclomethasone Dipropionate for Treating Perennial Allergic Rhinitis Patients,”Annals of Allergy, Asthma&Immunology, vol. 77, pp. 153-160, 1996.
Cayen Mitchell
Chaudry Imtiaz A.
Cuss Francis M.
Nagabhushan Nagamani
Nolop Keith B.
Baldwin Geraldine F.
Clardy S. Mark
Franks Robert A.
Lipka Robert J.
Schering Corporation
LandOfFree
Use of mometasone furoate for treating airway passage and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of mometasone furoate for treating airway passage and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of mometasone furoate for treating airway passage and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3385799